Physician profile
Anmol Rangoola
NPI 1700320025
$29,202.71
in general payments reported to CMS, 2019-2025
44 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,122 · 2022: $2,233 · 2023: $1,636 · 2024: $3,501 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $6,233 · Travel and Lodging: $3,425 · Consulting Fee: $1,125 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,965.00 |
| Food and Beverage | $6,232.95 |
| Travel and Lodging | $3,424.80 |
| Consulting Fee | $1,125.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12,985.29 | 2021-2025 | |
| Janssen Biotech, INC. | $6,079.94 | 2021-2025 | Carvykti, Rybrevant, Erleada |
| Seagen INC. | $1,823.06 | 2021-2023 | Padcev |
| Janssen Scientific Affairs, LLC | $1,362.67 | 2023-2024 | Akeega, Erleada |
| Merck Sharp & Dohme LLC | $971.70 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $683.36 | 2021-2025 | Padcev, Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $589.74 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $450.19 | 2023-2025 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $422.45 | 2021-2025 | Opdivo |
| Blue Earth Diagnostics | $341.86 | 2021-2024 | |
| Dendreon Pharmaceuticals LLC | $327.54 | 2021-2025 | Provenge |
| Novartis Pharmaceuticals Corporation | $307.28 | 2021-2025 | |
| Progenics Pharmaceuticals, INC. | $300.62 | 2021-2024 | Pylarify |
| Gilead Sciences, INC. | $294.29 | 2021-2024 | Trodelvy |
| Urogen Pharma, INC. | $248.84 | 2023-2025 | Jelmyto |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $224.56 | 2021-2024 | |
| Emd Serono, INC. | $218.07 | 2022-2024 | Bavencio |
| Biotissue Holdings INC. | $188.98 | 2023 | |
| Telix Pharmaceuticals | $167.07 | 2024 | Illuccix |
| Myovant Sciences INC. | $133.79 | 2021-2022 | |
| Caris Mpi, INC. | $107.61 | 2025 | Mi Cancer Seek |
| Amgen INC. | $103.25 | 2021-2023 | Xgeva, Nplate, Vectibix |
| Abbvie INC. | $98.53 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $97.53 | 2021-2025 | Enhertu |
| Lilly USA, LLC | $97.52 | 2024 | Verzenio, Retevmo, Jaypirca |
| Array Biopharma INC | $81.31 | 2021 | |
| Sumitomo Pharma America, INC. | $80.75 | 2024-2025 | Orgovyx |
| Daiichi Sankyo INC. | $45.55 | 2024-2025 | Enhertu |
| Tersera Therapeutics LLC | $38.97 | 2024 | Zoladex |
| Tempus Ai, INC | $31.93 | 2025 | Xt Cdx |
| Genzyme Corporation | $29.79 | 2023 | |
| 180 Medical, INC. | $29.63 | 2024 | |
| Incyte Corporation | $23.88 | 2021 | |
| Convatec INC. | $22.90 | 2023 | |
| Intuitive Surgical, INC. | $21.54 | 2022 | |
| Genentech USA, INC. | $21.48 | 2024 | Phesgo, Perjeta |
| Foundation Medicine, INC. | $20.28 | 2023 | Foundationone Liquid Cdx |
| Ferring Pharmaceuticals INC. | $19.99 | 2024 | Adstiladrin |
| Mimedx Group, INC. | $19.67 | 2024 | |
| Smith+Nephew, INC. | $18.92 | 2021 | |
| Immunitybio, INC. | $18.55 | 2025 | |
| Baxter Healthcare | $17.69 | 2022 | |
| Tolmar, INC. | $17.45 | 2023 | |
| Myriad Genetic Laboratories, INC. | $16.69 | 2024 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anmol Rangoola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.